Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | TEK | Q02763 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16612806 | 0.80 | EGFR (0.41) | EGFRIGF1RSRCKDRTEK | |
| SCHEMBL3124523 | 0.76 | PRKCI (0.46) | IGF1RKDRAXLPRKCIADORA2A | |
| SCHEMBL29700716 | 0.75 | PRKCI (0.44) | IGF1RKDRAXLPRKCIADORA2A | |
| SCHEMBL691603 | 0.75 | PRKCI (0.44) | IGF1RKDRAXLPRKCIADORA2A | |
| SCHEMBL16743055 | 0.73 | TYRO3 (0.40) | KDRAXLPRKCIADORA2AADORA1 | |
| SCHEMBL13666508 | 0.72 | PRKCI (0.41) | AXLPRKCIADORA2AADORA1DYRK1A | |
| SCHEMBL31507871 | 0.72 | CHUK (0.51) | AXLPRKCIADORA2AADORA1DYRK1A | |
| SCHEMBL2147990 | 0.72 | PRKCI (0.41) | AXLPRKCIADORA2AADORA1CYP1A2 | |
| SCHEMBL17731733 | 0.72 | PRKCI (0.41) | EGFRAXLPRKCIADORA2AADORA1 | |
| SCHEMBL760829 | 0.72 | CHUK (0.51) | AXLPRKCIADORA2AADORA1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9512161-B2 | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | INCYTE CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512161-B2 | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | INCYTE CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512161-B2 | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile | INCYTE CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| EP-2014659-A1 | New hybrid compounds of nucleobases and organic redox molecules and their use | Universität Osnabrück (DE) | 2009-01-14 | — | — | EP | disclosed |
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| CN-101133056-A | Antitumor compounds | NAT HEALTH RESEARCH INSTITUTES (CN) | 2008-02-27 | — | — | CN | disclosed |
| EP-1838711-A2 | ANTI-TUMOR COMPOUNDS | National Health Research Institutes (TW) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074041-A2 | ANTI-TUMOR COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148801-A1 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-06 | — | — | US | disclosed |
| US-3988338-A | PLANT GROWTH REGULATORS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | EGFR 863/4885IGF1R 1389/4885SRC 140/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | EGFR 863/4885IGF1R 1389/4885SRC 140/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | EGFR 863/4885IGF1R 1389/4885SRC 140/4885 |
| US-20060148801-A1 | Anti-tumor compounds | TUBB1, TUBB3, TUBB | EGFR 1456/4885IGF1R 2776/4885SRC 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.